天宇股份(300702.SZ)：公司整体研发投入将保持稳定，每年约2.5-2.8亿元

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) maintains a stable annual R&D investment of approximately 250-280 million yuan, with a shift in focus towards raw materials and CDMO R&D while decreasing investment in generic drug formulations [1] Group 1: R&D Investment - The company plans to keep its overall R&D investment steady at around 250-280 million yuan each year [1] - There is an increasing proportion of R&D investment allocated to raw materials and CDMO, while the investment in generic drug formulations is gradually declining [1] Group 2: Sales Expenses - The sales expenses for the formulation business are growing rapidly due to its fast development [1] - The company is enhancing its marketing management through the establishment of a digital system [1]